References

the protein product of the Duchenne/Becker muscular dystrophy gene

10.1016/0968-0004(89)90290-9 · 1989 · External reference

The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy

10.1083/jcb.201212142 · 2013 · External reference

Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis

10.1212/wnl.0000000000012910 · 2021 · External reference

Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study

10.3233/jnd-230107 · 2024 · External reference

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy

10.1002/ana.24555 · 2016 · External reference

Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases

10.1016/j.ymthe.2025.04.038 · 2025 · External reference

Unresolved reference

2023 · External reference

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

10.1038/s41591-024-03304-z · 2025 · External reference

Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy: The Ethics and Financial Toxicity of Exuberant Hope

10.1212/wnl.0000000000214085 · 2025 · External reference

Assembly, nuclear import and function of U7 snRNPs studied by microinjection of synthetic U7 RNA into Xenopus oocytes

10.1093/nar/23.16.3141 · 1995 · External reference

Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs

10.1073/pnas.95.9.4929 · 1998 · External reference

U7 snRNA, a Small RNA with a Big Impact in Gene Therapy

2021 · External reference

Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping

10.1126/science.1104297 · 2004 · External reference

U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping

10.1007/s000180300047 · 2003 · External reference

U7 snRNA: A tool for gene therapy

10.1002/jgm.3321 · 2021 · External reference

Pseudoexons of the DMD Gene

10.3233/jnd-190431 · 2020 · External reference

Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort

10.1002/ajmg.a.30617 · 2005 · External reference

Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy

10.1002/humu.24343 · 2022 · External reference

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

2021 · External reference

Eteplirsen for the treatment of Duchenne muscular dystrophy

10.1002/ana.23982 · 2013 · External reference

Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study

10.1002/acn3.51235 · 2020 · External reference

Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer

10.1182/blood-2011-09-382317 · 2012 · External reference

Durability of transgene expression after rAAV gene therapy

10.1016/j.ymthe.2022.03.004 · 2022 · External reference

Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model

10.1016/j.omtm.2023.101144 · 2023 · External reference

Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping

10.1089/hum.2020.286 · 2021 · External reference

Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping

10.1016/j.omtm.2021.03.014 · 2021 · External reference

A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype

10.1186/1743-422x-10-74 · 2013 · External reference

AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy

10.1093/nar/gkaf241 · 2025 · External reference